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Atherosclerosis is a chronic arterial disease in which complex mechanisms contribute to lesion initiation and development [1] . Many biochemical and cellular mechanisms have been invoked to describe the evolution of this pathology. There has been a recent focus on diverse roles of microRNAs (miRs) as drivers of the molecular basis of atherosclerotic lesion formation. miRs are a class of small noncoding RNAs (approximately 22 nucleotides) that regulate many physiological and pathophysiological functions through repression of protein translation or promoting mRNA instability. This commentary is a summary of recent selected publications that have provided an insight into roles of miRs in atherosclerosis.
Dysfunction in cholesterol metabolism remains a core mechanism of atherosclerotic formation. To gain an insight into a link of cholesterol metabolism and miRs, Rayner et al.
[2] manipulated macrophage sterol content and performed an unbiased genomewide screen of miRs. Several candidates were identified including miR-33 that is encoded within intron 16 of sterol regulatory element-binding protein 2 (SREBF2), a transcriptional factor that modulates cholesterol homeostasis. miR-33 expression decreased plasma HDL-cholesterol concentrations in mice through suppressing two cellular sterol transporters, ABCA1 and ABCG1. The authors' subsequent study demonstrated that miR-33 inhibition influenced atherosclerosis. This was determined in low-density lipoprotein receptor À/À (Ldlr À/À ) mice fed a saturated fat-enriched diet for 14 weeks to promote formation of lesions [3 && ]. Simultaneously with switching to a normal laboratory diet, one group was subcutaneously injected with miR-33 antisense oligonucleotides and compared to groups injected with either vehicle or control miRs. Lesion size in aortic roots of mice administered miR-33 antisense oligonucleotides were impressively decreased 4 weeks later. Although this reduction was associated with only modest increases in plasma HDL-cholesterol concentrations, miR-33 antisense oligonucleotides promoted large increases in reverse cholesterol transport. In addition to the profoundly decreased atherosclerosis, anti-miR-33 oligonucleotides penetrated atherosclerotic lesions and targeted to macrophages, which led to diminished inflammatory gene expression.
These two studies provide strong evidence that inhibition of miR-33 could be an effective antiatherosclerotic strategy. A potentially confounding factor in extrapolation of these studies to humans is that mice only possess miR-33a, in contrast to the presence of both miR-33a and miR-33b in higher classes of mammals. To address this issue, studies were performed using a nonhuman primate, African green monkeys [4 && ]. Monkeys were injected subcutaneously with an antisense oligonucleotide that equally inhibited both miR-33a and miR-33b for 12 weeks, while being fed a high carbohydrate during the last 8 weeks. As in mice, inhibition of both miR-33s resulted in increased plasma HDL-cholesterol concentrations [2,3 && ,4 && ]. Further potential benefit was noted in monkeys with miR-33 inhibition promoting significant reductions of plasma triglyceride concentrations attributed to decreases in VLDL-triglyceride concentrations. The intriguing data regarding the effects of miR-33a and miR-33b in cholesterol metabolism and other metabolic disorders have been reviewed recently [5] . In aggregate, these preclinical findings provide insights that inhibition of miR-33 is a promising therapeutic strategy for atherosclerosis in humans.
Although miR-33 contributes to atherosclerosis via disruption of cholesterol homeostasis, several other miRs influence lesion formation through effects on immune cell activation, endothelial cell function, vascular smooth muscle cell phenotypes, or crosstalk among different cell types. For example, miR-143 and miR-145 are well characterized in regulation of vascular smooth muscle cell differentiation [6 & ]. This function of the two miRs implicates a potential role in atherosclerosis development through influencing vascular smooth muscle cell phenotypes [7] [8] [9] . A recent study has also reported a novel function of these two miRs in regulating atherosclerosis through interactions between endothelial and smooth muscle cells [10 && ]. The shear-responsive transcription factor Krüppellike factor 2 (KLF2) was initially studied in cultured human endothelial cells and found that enhanced KLF2 abundance increased both miR-143 and miR-145. Subsequent experiments discovered that miR-143 and miR-145 communicated between endothelial cells and smooth muscle cells through transporting these two miRs in extracellular vesicles from endothelial cells to smooth muscle cells. The importance of the two miRNAs was demonstrated by miR-143 and miR-145 enriched extracellular vesicles derived from KLF2-expressing endothelial cells attenuating atherosclerosis in the aorta of Apoe À/À mice. These findings add another exciting layer to potential effective therapies using certain miRs as a target.
In a summary, cell culture studies and animal models are providing accumulating evidence that miRs exert critical roles in the development or prevention of atherosclerosis. Although pharmacological modulation of miRs may provide promising therapeutic approaches for atherosclerosis, further studies are necessary to determine whether the current findings in animal models can be translated into effective therapies in clinical patients.
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